Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy.
Kernt
Marcus
M
Gschwendtner
Andreas
A
Neubauer
Aljoscha S
AS
Dichgans
Martin
M
Haritoglou
Christos
C
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D012161:Retinal Artery / Q000187:drug effects / Q000503:physiopathology; D012164:Retinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab